The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 12 January 2004, www.theannals.com, DOI 10.1345/aph.1D415.
 The Annals of Pharmacotherapy: Vol. 38, No. 3, pp. 396-399. DOI 10.1345/aph.1D415
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nahata, M. C
Right arrow Articles by Morosco, R. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nahata, M. C
Right arrow Articles by Morosco, R. S

PEDIATRICS

Stability of Lisinopril in Two Liquid Dosage Forms

Milap C Nahata, PharmD

Professor of Pharmacy and Division Chair, College of Pharmacy; Professor of Pediatrics and Internal Medicine, College of Medicine and Public Health, Ohio State University and Children's Hospital, Columbus, OH

Richard S Morosco

Research Associate, College of Pharmacy, Ohio State University

Reprints: Milap C Nahata PharmD, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210-1291, fax 614/292-1335

BACKGROUND: Lisinopril is used in pediatric patients with hypertension. It is not commercially available as a liquid. Little is known about the stability of lisinopril in extemporaneously prepared liquid dosage forms.

OBJECTIVE: To determine the stability of lisinopril in 2 oral suspensions stored at 4 and 25 °C in plastic prescription bottles.

METHODS: Five bottles contained methylcellulose 1%:simple syrup NF (1:13) and the other 5 bottles had Ora Plus-Ora Sweet (1:1) at a lisinopril concentration of 1 mg/mL. Three samples were collected from each bottle at 0, 7, 14, 28, 42, 56, 70, and 91 days and analyzed by stability-indicating HPLC analytical method (n = 15).

RESULTS: At 4 °C, the mean ± SD concentration of lisinopril remained >95.1 ± 1.8% of the initial concentration in the methylcellulose formulation and 95.1 ± 3.2% of the initial concentration in the Ora Plus-Ora Sweet formulation throughout the 91-day study period. At 25 °C, the mean concentration of lisinopril remained >92.4 ± 2.2% of the initial concentration in the methylcellulose formulation for 8 weeks and 95.8 ± 2.3% of the initial concentration in the Ora Plus-Ora Sweet formulation throughout the 91-day study period. No changes in physical appearance in any samples were seen during this period.

CONCLUSIONS: Lisinopril can be prepared in either of 2 liquid dosage forms and stored for at least 13 weeks under refrigeration and 8 weeks at room temperature.

Key Words: lisinopril, pediatrics, stability

Published Online, January 12, 2004. www.theannals.com, DOI 10.1345/aph.1D415




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.